Paschali A, Panagiotidis E, Triantafyllou T, Palaska V, Tsirou K, Verrou E, Υiannaki E, Markala D, Papanikolaou A, Pouli A, Konstantinidou P, Chatzipavlidou V, Terpos E, Katodritou E
Department of Nuclear Medicine, Theagenion Cancer Hospital, Thessaloniki, Greece.
Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1487-1497. doi: 10.1007/s00259-020-05078-1. Epub 2020 Oct 25.
The investigation of a semi-quantitative index in the pelvis to assess for diffuse bone marrow (BM) [18F]-FDG uptake and the investigation of PET skeletal patterns in multiple myeloma (MM) patients, in accordance with prognostic markers, clonal plasma cell (cPC) morphology, and response to therapy.
We prospectively analyzed [18F]-FDG PET/CT in 90 MM patients (newly diagnosed, 60; relapsed/refractory, 30). Among other PET/CT parameters, we calculated the ratio SUVmax pelvis/liver and examined for correlations with known MM prognostic parameters, cPC morphology (good vs. low/intermediate differentiation), and response to therapy.
SUVmax pelvis/liver ratio was significantly lower for the group of good differentiation vs. intermediate/low differentiation cPCs (p < 0.001) and showed a positive correlation with BM infiltration rate, β2 microglobulin, serum ferritin, international staging system (ISS), and revised ISS; no significant correlation was found with hemoglobin. A cutoff value of 1.1 showed an excellent specificity (99%) and high sensitivity (76%) for diffuse BM involvement (AUC 0.94; p < 0.001). Mixed pattern and appendicular involvement correlated with poor prognostic features while normal pattern, found in 30% of patients, correlated with good prognostic features. Presence of ≥ 10 focal lesions negatively predicted for overall response (p < 0.05; OR 4.8). The CT component improved the diagnostic performance of PET.
This study showed, for the first time, that cPC morphology and markers related with MM biology, correlate with SUVmax pelvis/liver index, which could be used as a surrogate marker for BM assessment and disease prognosis; PET patterns correlate with MM prognostic features and response rates.
研究骨盆中的半定量指标,以评估弥漫性骨髓(BM)[18F]-FDG摄取情况,并根据预后标志物、克隆性浆细胞(cPC)形态及治疗反应,研究多发性骨髓瘤(MM)患者的PET骨骼模式。
我们前瞻性分析了90例MM患者(新诊断患者60例,复发/难治性患者30例)的[18F]-FDG PET/CT。在其他PET/CT参数中,我们计算了SUVmax骨盆/肝脏比值,并检查其与已知MM预后参数、cPC形态(高分化与低/中分化)及治疗反应的相关性。
高分化cPC组的SUVmax骨盆/肝脏比值显著低于中/低分化cPC组(p < 0.001),且与骨髓浸润率、β2微球蛋白、血清铁蛋白、国际分期系统(ISS)及修订后的ISS呈正相关;与血红蛋白无显著相关性。截断值为1.1时,对弥漫性骨髓受累具有极佳的特异性(99%)和高敏感性(76%)(AUC 0.94;p < 0.001)。混合模式和四肢受累与不良预后特征相关,而30%的患者出现的正常模式与良好预后特征相关。≥10个局灶性病变的存在对总体反应具有负向预测作用(p < 0.05;OR 4.8)。CT部分提高了PET的诊断性能。
本研究首次表明,cPC形态及与MM生物学相关的标志物与SUVmax骨盆/肝脏指数相关,该指数可作为骨髓评估和疾病预后的替代标志物;PET模式与MM预后特征及反应率相关。